Johnson & Johnson says TREMFYA improved spinal pain, stiffness in PsA study

Johnson & Johnson said TREMFYA (guselkumab) was the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in a landmark axial psoriatic arthritis study.